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ABSTRACT:
Tumor biology is a broad and encompassing field of research, particularly given 
recent demonstrations of the multicellular nature of solid tumors, which have led 
to studies of molecular and metabolic intercellular interactions that regulate cancer 
progression. Hypoxia is a broad stimulus that results in activation of hypoxia inducible 
factors (HIFs). Downstream HIF targets include angiogenic factors (e.g. vascular 
endothelial growth factor, VEGF) and highly reactive molecules (e.g. nitric oxide, NO) 
that act as cell-specific switches with unique spatial and temporal effects on cancer 
progression. The effect of cell-specific responses to hypoxia on tumor progression and 
spread, as well as potential therapeutic strategies to target metastatic disease, are 
currently under active investigation. Vascular endothelial remodelling events at tumor 
and metastatic sites are responsive to hypoxia, HIF activation, and NO signalling. 
Here, we describe the interactions between endothelial HIF and NO during tumor 
growth and spread, and outline the effects of endothelial HIF/NO signalling on cancer 
progression. In doing so, we attempt to identify areas of metastasis research that 
require attention, in order to ultimately facilitate the development of novel treatments 
that reduce or prevent tumor dissemination.  
INTRODUCTION
In the last decade, tumors have been redefined as 
multicellular organs, a notion that replaced the previously 
confined view that tumors are pluricellular masses [1], and 
which restricted both the understanding of the biology of 
cancer, and the development of effective therapeutic 
strategies. Specific and substantial roles of non-
malignant cells in cancer progression (tumor growth and 
metastasis) have recently been elucidated, and therapeutic 
focus has begun to shift away from the tumor cells 
themselves towards a broader spectrum of cellular and 
molecular targets [2, 3], all inter-dependent components 
of a plastic, adaptive and mobile organ with powerful 
survival strategies. Despite vast research on the tumor 
microenvironment, however, alternative cancer treatments 
aimed at non-malignant cells remain elusive [4-6].
The processes of tumor growth and dispersion are 
highly complex, given that each cell type responds to 
different stimuli in a unique fashion. Multiple biochemical, 
mechanical, and signalling pathways define disease 
advancement, and in doing so, modulate clinical outcome 
[5-7]. Assessing the progression of cancer is currently 
forced to incorporate this organic complexity whereby 
the contribution of different cell types to the processes of 
tumor growth, aggressiveness, dispersion and response 
to therapy is accounted for. Therefore, physiological 
and metabolic adaptations of cells within the tumor and 
metastatic environment have to be assessed individually 
and taking into consideration the synergistic impact on the 
others [7, 8]. 
Tumor growth and spread is strongly affected by, for 
example, the endothelial cell (EC) response to hypoxia [9]. 
We and others recently demonstrated that this response 
controls metastatic success, to a significant extent, via 
hypoxia-inducible factors (HIFs) [10, 11] and nitric oxide 
(NO) [11]. Our study unveiled a role for endothelial 
HIF/NO-dependent signalling in metastasis, which is 
differentially regulated by the two major HIF isoforms 
(HIF1-alpha and HIF2-alpha) that severely impact upon 
the ability of tumor cells to successfully establish distant 
metastases [11]. In this study, HIF1-alpha was shown to 
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have a pro-metastatic effect, while HIF2-alpha opposed 
metastasis, and although we speculated that these 
effects occur via NO- and vascular endothelial growth 
factor (VEGF)-mediated changes in vessel permeability 
(Figure 1), the mechanisms by which endothelial HIF/
NO signalling intervenes in metastasis are not fully 
understood. The aim of this perspective is to summarise 
the diverse functions of endothelial and HIF/NO signalling 
during cancer progression, and to discuss the potential 
impact of these findings on future studies leading towards 
the development of novel adjunctive cancer therapies.
HIF-mediated response to hypoxia during cancer 
progression
Hypoxia is a trademark of solid tumors that is 
associated with poor prognosis and successful metastases 
[12-14]. The HIF-mediated control of this response has 
been comprehensively characterized [15-18], and the role 
of these transcription factors is presently acknowledged to 
be cell-specific [19]; mechanisms and factors regulating 
HIF-a stability as well as the target genes and pathways 
regulated by them vary between different cell types and 
in different conditions, which include stimuli other than 
hypoxia [12, 19]. 
For that reason, the attractive strategy of targeting 
HIF1-alpha for cancer therapy needs to be observed 
and integrated in a multicellular and temporal context; 
Although HIF1-alpha (and in some cases HIF2-alpha) 
activity in tumor cells, for example, is a clear indicator 
of poor prognosis [12, 17, 20], in other cell types this 
may not be the case [11]; many other non-malignant 
cell types within the tumor microenvironment have been 
shown to significantly contribute to the regulation of 
cancer progression [3], especially macrophages [21, 22] 
and fibroblasts [23] which, among other things, greatly 
contribute to the paracrine VEGF signalling that leads 
to aberrant vascularization. ECs, specifically, both at the 
tumor stroma [24] and at the extravasation sites [11] also 
have unique responses to hypoxia [25, 26] and play a 
critical role tumor dispersion [24]. 
Endothelial cell-specific response to hypoxia
ECs are mostly glycolytic and their hypoxic 
response is triggered at lower oxygen concentrations 
compared with other cell types [25]. Although the 
machinery and capacity to respond to less severe hypoxia 
is present and functional in ECs, this discrepancy appears 
to involve intricate mechanisms, and the activation of HIF 
in these cells is sensitive to minor oscillations in oxygen 
tension as well as other chemical signals [26-28]. 
Reductions in oxygenation that occur in a solid 
tumor directly impact upon the endothelium, which can 
act as a barrier or vehicle for metastasising cells. Hypoxic 
conditions, as mentioned above, are associated with a 
leaky and inefficient vasculature that compromises the 
barrier function of the blood vessels against infiltrating 
cells. At the site of extravasation, hypoxia could occur 
locally, for example, when migrating cells arrest in the 
capillary bed prior to seeding at secondary sites [29, 30].
In the case of the characteristic tortuous and 
inefficient tumor vasculature, the blood flow and 
consequently oxygen delivery is insufficient. ECs sense 
and respond to this stimulus by activating mechanisms 
that lead to increased proliferation; this is supported by 
an increase in endogenous and exogenous VEGF levels 
and associated receptors, migration (required for vascular 
branching and angiogenesis) and activation of hypoxic 
metabolism that ensures survival and amelioration of the 
hypoxic condition [31]. Specifically, tumor ECs: (i) enable 
the delivery of oxygen and nutrients to the tumor; (ii) 
form a physical barrier between the tumor mass and the 
remaining organism; (iii) act as a vehicle through which 
detached tumor cells travel to distant organs; and (iv) 
provide an anchor required for survival of micrometastases 
[32, 33]. By directly interacting with other cell types in the 
tumor microenvironment (e.g. inflammatory cells, tumor 
cells, platelets), ECs can aid or impair tumor growth and 
spread [7, 34, 35].
Mechanisms that regulate the generation and 
function of the tumor vasculature have therefore been the 
target of many experimental and clinical studies that aim 
to reduce tumor propagation [36]. Although tumor size 
is often initially reduced by anti-angiogenic treatments 
(e.g. HIF and VEGF inhibitors), such therapies frequently 
have short-lived effectiveness, and long term benefits 
are not only seldom observed, but can also result in 
higher metastatic incidence [4, 37]. These findings have 
highlighted the complex and multi-factorial nature of the 
HIF-mediated angiogenic response to hypoxia during 
cancer progression [27, 38], one component of which is 
regulated solely by EC-specific HIF.
HIF-mediated response in hypoxic EC during 
cancer progression 
Effects of EC-specific HIF signalling on cancer 
progression have been elucidated in the last decade, 
often using Cre-LoxP-mediated deletion of EC HIF-
alpha driven by the Tie2 or VE-cadherin promoters in 
mice [11, 12]. Mice with EC-specific deletion of HIF1-
alpha, for example, develop smaller subcutaneous tumors 
compared with those implanted into wild-type littermates 
[27]; EC-specific deletion of HIF2-alpha compromises 
neovascularization and vessel remodelling [38]. EC-
specific HIF1-alpha knockout also reduces metastases in 
the Polyoma middle T (PyMT) mouse model of mammary 
cancer, and attenuates extravasation in mice subjected to 
intravenous tumor cell injections [11]. 
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Studies using mouse models of cancer with EC-
specific deletion of HIF2-alpha have also shown reduced 
tumor growth rates compared with wild type mice [10], 
but the effect of EC-specific HIF2-alpha deletion on 
metastatic efficiency in these mice has been reported as 
being advantageous [10] and deleterious [11]. The role 
of the endothelium in mediating metastatic disease, the 
location and timing of HIF-signalling and the contribution 
of NO to cancer progession is a puzzle with possibly 
multiple solutions. It is therefore worthwhile identifying 
the pathways activated downstream of these main 
regulators as potential targets for therapy, in alternative or 
in addition to targeting them directly. 
The role of EC-specific HIF signalling in metastatic 
disease is an active area of research in our laboratory. In 
multiple cell types, one important downstream effector of 
the HIF-mediated responses is the metabolic regulator, 
NO [39-41]. In addition to all the functions performed by 
this highly reactive molecule, there is currently a plethora 
of information that directly correlates NO with cancer 
progression, metastases and clinical outcome [42, 43].
Response to hypoxia during cancer progression: 
contribution of Nitric Oxide
NO is an ephemeral but highly reactive molecule 
with direct cytotoxic effects [44]. NO can be generated as 
a result of hypoxia, given that the inducible form of nitric 
oxide synthase (iNOS) is a target of HIF1-alpha [45, 46]. 
Conversely, NO can also be a cause for metabolic hypoxia, 
given that competition with oxygen at cytochrome c results 
in diversion of oxygen to other pathways [46, 47]. NO 
has also been shown to increase HIF1-alpha degradation 
during hypoxia [48], and is negatively correlated with 
blood oxygen saturation, for example during arthritis 
development [49].
NO signalling in cancer progression and 
metastases.  
During carcinogenesis, NO is generated by 
different cell types, in different amounts, and via 
different regulatory mechanisms [39]. In human breast 
tumors, for example, higher levels of NO are found in 
malignant tissues compared with benign masses, and 
these levels increase as tumors progress, independent of 
other prognostic parameters such as estrogen receptor 
level, human epidermal growth factor receptor (HER) or 
menopausal status [50]. 
Although the role of NO is well established in other 
pathological settings, such as the regulation of vascular 
tone, the inflammatory response, and mitochondrial 
respiration [48, 51-53] its impact on tumor progression 
and metastatic processes appears ambiguous [44, 54]. 
Studies have previously suggested both facilitating and 
hampering effects of NO on tumor growth and metastatic 
success. 
NO is known to function as a pro-apoptotic agent 
[54-56] and as such can promote tumor cell death [39]. 
This property has lead to the suggestion that NO donors 
could be used to limit tumor growth, and it has also been 
argued that NO donors could improve efficacy of chemo 
and radiotherapy by counteracting desensitization and 
resistance [57-59]. 
On the other hand, findings that argue for a pro-
tumorigenic role of NO are varied. For example, excessive 
Figure 1: Endothelial HIF/NO-mediated regulation of metastases at primary tumor and metastatic sites.  (A) Hypoxia 
and subsequent HIF-a stabilization are common trademarks of solid tumors, which affect the myriad of cellular components within the 
tumor, and lead to cell type-specific responses, including NO-mediated endothelial remodelling that increases vascular leakiness and drives 
intravasation. (B) Endothelial HIF and NO signalling also affect extravasation and possibly post-extravasation proliferation of tumor cells; 
remodelling responses to HIF activation and NO induction in the endothelium, however, can be tissue- and isotype-specific.
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levels of NO and subsequent oxidative stress, lead to 
DNA and protein damage, thereby increasing mutation 
rates and consequently enhancing tumor aggressiveness 
[44, 55]; Furthermore, iNOS expression in many human 
and murine cancers correlates with poor prognosis and 
decreased disease-free survival [41, 60]. NO is also known 
as a mediator of angiogenesis [41], therefore contributing 
to tumor growth and dissemination. NO-driven metabolic 
hypoxia was also shown to affect angiogenesis, 
hyperplasia, and the formation of inflammatory lesions 
breast cancer patients [50] while iNOS depletion or 
inhibition in murine breast cancer models consistently 
results in reduced tumor growth and metastases [11, 61, 
62]. The presence of NO has also been shown to decrease 
immune cell-mediated tumor cell death via inhibition 
of HIF1 under hypoxia [59], and chemokine nitration 
within the tumor microenvironment appears to be one 
of the mechanisms by which tumor NO prevents T-cell 
infiltration [40, 63].
Although NO is clearly produced in tumor cells 
[40, 41, 60, 61, 64], alternative cellular sources of NO 
are seldom reported, as are their spatial and temporal 
expression patterns of the NOS isoforms. Moreover, 
metabolic effects of NO on cancer progression at the 
primary tumor site and particularly at the site of metastasis 
require further investigation.
HIF and/or NO: coordinated regulation of EC 
metabolism during tumor growth and metastasis
A number of studies have investigated the potential 
effects of endothelial HIF-mediated NO signalling 
Table 1: Studies investigating the role of endothelial HIF/NO/VEGF signalling in cancer progression
Methods Results Conclusions Ref
EC HIF1-alpha and 2-alpha 
knockout mice with:
  (a) Implanted subcutaneous and 
spontaneous mammary tumors
  (b) Intravenous Lewis lung cancer 
cells
Migration of cancer cells across ECs
EC HIF1-alpha knockout reduced:
  (a) NO synthesis
  (b) Cancer cell migration across 
ECs 
  (c) Metastatic success
EC HIF2-alpha knockout had the 
opposite effect
EC HIF1-alpha and HIF2-
alpha have opposing roles in the 
regulation of metastatic seeding
HIF-alpha acts in a cell- and 
isoform-specific manner
[11]
Analysis of human mammary tumor
eNOS, HIF1-alpha, iNOS, and 
VEGF, were present
There were correlations between:
  (a) eNOS and HIF1-alpha, VEGF, 
or VEGFR2
  (b) VEGF and VEGFR2 
HIF1-alpha/NO/VEGF signalling 
appears to be active in human 
breast cancer
[87]
EC HIF2-alpha knockout mice with 
autochthonous skin tumors
Migration, proliferation, adhesion, 
and invasion of HIF2-alpha 
knockout ECs
EC HIF2-alpha knockout impaired:
  (a) Functional tumor angiogenesis
  (b) Tumor perfusion
  (c) Adhesion to collagen
EC HIF2alpha knockout increased:
  (a) Migration and invasion
  (b) Tube formation 
EC HIF2-alpha is required for 
tumor vessel growth
Roles of EC HIF1alpha and 2alpha 
in pathological angiogenesis are 
distinct
[38]
Analysis of human esophageal 
tumor
HIF1-alpha was present in tumors
There were associations between:
  (a) HIF1-alpha, VEGF, and iNOS
  (b) eNOS and VEGF
HIF1-alpha, iNOS, and VEGF 
expression is linked in human 
esophageal cancer
[88]
EC HIF2-alpha knockout mice with 
xenograft tumors
Vascularisation, apoptosis, and 
adhesion of HIF2alpha knockout 
ECs
EC HIF2-alpha knockout impaired:
  (a) Vessel integrity
  (b) EC structure
  (c) Tumor angiogenesis
  (d) EC adhesion 
EC HIF2-alpha is required for 
normal EC function and vessel 
formation
EC HIF1-alpha and 2-alpha have 
distinct roles in angiogenesis
[10]
EC HIF1-alpha knockout mice with 
implanted subcutaneous tumors
Proliferation, migration, invasion, 
and tube formation of HIF1-alpha 
knockout ECs
EC HIF1alpha knockout inhibited:
  (a) Proliferation, migration, and 
invasion
  (b) Tumor angiogenesis and 
growth
EC HIF1/VEGF signalling is 
crucial for cell function during 
tumor angiogenesis
[27]
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on cancer progression (Table I). It has been shown, 
for example, that cyclic hypoxia (likely induced by 
heterogeneous and deregulated blood flow in solid tumors) 
increases EC survival through HIF1-alpha stabilization, 
and that eNOS attenuates HIF1-alpha expression and 
interferes with cell respiration [26, 65]. Furthermore, EC 
survival in response to cyclic hypoxia is increased by NOS 
inhibition [65]. 
NO mimetic agents have also been shown to 
suppress HIF1-alpha accumulation under hypoxia [66]; 
interestingly, several studies report that the accumulation 
of angiogenic VEGF is directly correlated with NO 
levels [67, 68]. We showed that EC-specific VEGF levels 
decrease in the absence of iNOS expression or activity 
and increase in the presence of an NO donor, and that this 
occurs in direct correlation with metastatic success [11]. 
iNOS-dependent VEGF production has also been reported 
elsewhere [64, 69, 70].
The EC response to hypoxia affects processes that 
contribute to tumor progression and spread, including 
vessel permeability, tumor cell migration, proliferation, 
and interaction with other cells relevant for tumor cell 
seeding and establishment, including inflammatory 
cells and platelets [71-73] NO stimulates proliferation, 
migration, and differentiation of ECs to form new blood 
vessels [28], but again positive [74] and negative [75] 
effects of NO on vascular permeability have been reported.
Contrasting effects of endothelial HIF/NO 
signalling on cancer progression could again be a result of 
differences in cell/tissue type, NOS isoform, and NO levels 
between studies. Most studies on endothelial-derived 
NO production have been circumscribed to the levels 
and activity of eNOS, which is constitutively expressed 
and widely accepted as the major determinant of NO 
production in ECs. It has also been reported, however, that 
the major function of eNOS is to maintain residual levels 
of NO, which in turn ensures that endothelial permeability 
and vascular tension are stable [45]. Conversely, sharp 
and dramatic increases in NO levels are usually a result of 
iNOS activit; iNOS is more abundant and readily induced 
in murine compared with human ECs, which are more 
reliant on concomitant cytokine stimulation in addition 
to HIF1-alpha activation [45]. Endothelial cells from 
different tissues and organs, whether in physiological or 
cultured conditions also display different gene expression 
and stress responses [76, 77]; this is yet another level 
of intricacy of the mechanisms underlying cell-cell 
interactions that control or predispose certain vascular 
beds to metastatic events.
Given that EC behaviour varies between organs 
[77, 78], the effect of EC HIF/NO signalling on tumor 
growth and metastasis may also depend on cancer type and 
metastatic site. NO production in mouse models of breast 
cancer is directly correlated with VEGF levels, but the 
pathway(s) that link cell-specific HIF/NO signalling with 
cancer outcomes such as tumor growth and metastasis 
Figure 2: Filling the gaps in endothelial HIF-alpha, NO signalling and subsequent changes that can contribute to 
metastatic events. At the site of extravasation, endothelial HIF-1a or HIF-2a activation results in differential activation of iNOS, with 
direct influences on NO production. Hypoxia- and HIF-independent signals can also stimulate NO production, and the origin, concentration, 
and duration of NO may affect metastatic success. Downstream effects of endothelial HIF/NO signaling, such as endothelial permeability 
and endothelial cell-tumor cell adhesion, could be targeted to reduce or prevent extravasation.   
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remain incompletely understood. One current aim in 
our laboratory is therefore to fully characterise the HIF/
NO-mediated response to hypoxia in ECs, and to study 
downstream effects of EC HIF/NO signalling on cancer 
progression, using mouse models of cancer and cell-
specific deletion of HIF-alpha or iNOS. 
PERSPECTIVES: CURRENT AND 
FUTURE WORK
Key questions remain when characterizing the role 
of the vasculature in metastatic disease, e.g. what roles do 
EC-specific HIF and NO play during intravasation, and 
what cell-specific molecular signalling pathways regulate 
the extravasation and viability of colonizing cancer cells? 
Although mechanisms that regulate endothelial HIF/NO-
mediated cancer progression are not fully understood, 
therapeutic or gene-mediated disruption of this signalling 
cascade could potentially reduce metastatic success 
(Figure 2).
In the primary tumor microenvironment, it is known 
that hypoxia triggers HIF1-alpha stabilization in different 
cell types. Subsequently, target genes including VEGF are 
transcriptionally up-regulated and cooperate to facilitate 
tumor growth and intravasation [79]. Factors that regulate 
stabilization of the HIF isoforms and iNOS in ECs at the 
site of extravasation however, are largely unknown and 
may be hypoxia-independent [80, 81].
Transient hypoxic events are likely to occur when 
circulating tumor cells obstruct small capillaries, for 
example in the lungs. The molecular outcome of those 
events would depend on a myriad of factors including 
duration and severity of hypoxic stimulus, as well as cell 
type(s) affected, and this could ultimately determine the 
extent to which each HIF-alpha isoform is stabilised, and 
in turn affect local NO levels that control extravasation. 
HIF/NO signalling in ECs, for example, could regulate 
metastasis by affecting vessel permeability (via disruption 
of endothelial junctions) or interaction between the 
endothelium and tumor cells (via cell adhesion molecules). 
HIF and/or iNOS could also be stabilized at the site of 
extravasation prior to the arrival of colonizing tumor 
cells, as a result of tumor-derived signals that circulate 
systemically [82, 83] For example, hypoxia-independent 
chemical stimuli could arise from the primary tumor [15, 
73, 83].
Given that cancer cell extravasation and metastatic 
colonization are rate-limiting steps that involve reciprocal 
interactions between tumor cells and host stroma [84-86], 
it will be crucial to understand the molecular and cellular 
mechanisms that regulate these interactions. To investigate 
whether endothelial HIF-alpha and/or iNOS have any role 
in assisting or preventing the establishment of tumor cells 
at secondary metastatic sites, lung endothelium can be 
exposed to hypoxia in EC-specific HIF-alpha null, NO 
null, or wild type mice (Branco-Price, unpublished data), 
and metastatic foci subsequently quantified using a mouse 
model of extravasation [11]. In order to characterise the 
spatial and temporal patterns of HIF-alpha isoforms and 
NO expression during cancer progression, we are also 
currently quantifying their levels at various metastatic 
sites and stages of tumor development. 
Simple immunohistochemical and biochemical 
approaches can be used to investigate changes in cell-
specific HIF-alpha isoform stabilization and their 
associated changes in vascular integrity that modulate 
metastasis. These techniques can also be used to localise 
hypoxic foci and predict the stage of tumor development 
at which HIF-directed therapy would be beneficial or 
detrimental. Discovering whether HIF activation is a 
result of local hypoxic loci and/or systemic signals from 
the primary tumor would improve our understanding of 
metastasis significantly, and elucidation of HIF/NO-
mediated mechanisms that regulate tumor dispersion could 
lead to the development of novel therapies to counteract 
this process.
One of the questions that have to be addressed 
is which HIF-alpha isoforms in the lung endothelium 
of tumor bearing mice are active, alternatively or 
simultaneously, and what is regulating that equilibrium.
CONCLUSIONS
The EC HIF/NO signaling pathway plays a crucial 
role in cancer progression. Such cellular and molecular 
pathways may be targeted in order to reduce tumor 
growth and spread. Given that: (i) hypoxic stress can 
cause differing levels of induction of the two HIF-alpha 
isoforms; (ii) HIF/NO-mediated responses to hypoxia 
during cancer progression are cell type-specific; and (iii) 
current HIF-alpha inhibitors are not cell type- or HIF 
isoform-specific, novel therapies should attempt to target 
individual HIF isoforms in defined cell sub-populations 
within the tumor microenvironment. Alternative or 
additional therapeutic approaches could also arise through 
targeting of factors downstream of EC HIF/NO. 
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